CA

Craig Asher

Managing Director at OMX Ventures

Washington, District of Columbia

Overview 

Craig Asher is the Managing Director at OMX Ventures in Washington, D.C., with a strong background in venture capital and product management. He has served as a Managing Partner at Trancos Ventures and has held board positions at Constructive Bio and Aperiam Bio. Asher's career highlights include his role as Managing Director at OMX Ventures and his experience as a Managing Partner at Trancos Ventures, showcasing his expertise in venture capital and strategic leadership.

Work Experience 

  • Managing Director

    2020 - Current

    OMX Ventures is a committed capital fund continuing the work of Trancos Ventures and Vital Venture Capital in investing in bio tools and therapeutics startups primarily at the intersection of data/engineering and biology. We typically make our first investment in the Seed or Series A rounds, then reserve for every subsequent round. We aim to support the CEOs of our portfolio companies in go-to-market, product marketing, fundraising, hiring, intellectual property, product development, organizational structure, sales, manufacturing, and software development. We partner on every deal with other VCs.

OMX Ventures is investing at the convergence of biology and computing.

  • Managing Partner

    2016

    We are no longer making investments in new portfolio companies via Trancos Ventures. Instead we are making all investments in new portfolio companies via our fund OMX Ventures. We continue to make add-on investments in the existing Trancos Ventures companies.

  • Board Observer

    2022

  • Board Observer

    2022

Aperiam Bio partners with enzyme engineers to create and share stabilized, solubilized, and catalytically optimized proteins.

Raised $12,660,002.00 from Civilization Ventures, KdT Ventures, OMX Ventures, Axial VC and Saya Bio.

  • Investor

    2022

Replay is a genome writing company reprogramming biology by writing and delivering big DNA.

Raised $55,000,000.00 from OMX Ventures, Kohlberg Kravis Roberts, Artis Ventures (AV), Salt Ventures, DeciBio Ventures, Lansdowne Partners and Axial VC.

  • Board Member

    2021

VedaBio innovative platform for near-instant molecular detection.

Raised $40,000,000.00 from OMX Ventures and Kleinmuntz Associates.

  • Principal

    2008

    We are winding down Vital Venture Capital as we continue to exit our portfolio investments. We continue to make add-on investments in our existing companies.

  • Board Member

    2021

Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform.

Raised $7,783,799.00 from stealth.vc.

  • Board Observer

    2021

Articles About Craig

Relevant Websites